[Drug therapy of migraine].
Out of the knowledge of various headache syndromes the physician has to develop a clear diagnostical and therapeutical concept. This is especially true for migraine. Relevant pathophysiological hypotheses are presented e.g. the neurogenic-vascular model of migraine. Metoclopramide and domperidone in combination with mono-analgesics, ergotamine and nonsteroidal-antiinflammatory drugs are favoured in the treatment of the acute migraine attack. 2 to 4 mg ergotamine for the attack, respectively 16 to 20 mg per month should not be exceeded. Mixed compounds, containing ergots, analgesics, codeine, caffeine, tranquilizers and barbiturates should be avoided as these drugs may induce rebound-headache. A prophylaxis of migraine is indicated if a migraineur suffers from at least 2 attacks per month or if a migraine attack lasts longer than 4 days. In the first place, beta-blockers and flunarizine, in some cases verapamil or naproxen, should be used; the effect of dihydroergotamine is questionable. Because of its severe side effects, methysergide should only be given if all other prophylactic drugs fail. Naproxen is standard medication in the short time prophylaxis of menstrual migraine.
Pfaffenrath
V
V
Reiter
M
M
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use; D000932:Antiemetics / Q000627:therapeutic use; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004087:Dihydroergotamine / Q000627:therapeutic use; D006801:Humans; D008125:Locus Coeruleus / Q000187:drug effects; D008784:Methysergide / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology; D011903:Raphe Nuclei / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D000932:Antiemetics; D004087:Dihydroergotamine; D008784:Methysergide
Medikamentöse Therapie der Migräne.